natgillin/translations-raw huggingface dataset:
On the basis of this immunogenicity bridging, the efficacy of Gardasil 9 in girls and boys aged 9 to 15 years is inferred. 
Na osnovi primerjave imunogenosti lahko sklepamo o učinkovitosti cepiva Gardasil 9 pri deklicah in dečkih, starih 9 do 15 let.
Gardasil 9 can be given with a combined booster vaccine containing diphtheria (d) and tetanus (T) with either pertussis [acellular, component] (ap) and/or poliomyelitis [inactivated] (IPV) (dTap, dT-IPV, dTap-IPV vaccines) at a separate injection site (another part of your body, for example the other arm or leg) during the same visit. 
Cepivo Gardasil 9 se lahko ob istem obisku uporabi sočasno s kombiniranim obnovitvenim cepivom proti davici (d) in tetanusu (T) ter oslovskemu kašlju [acelularno, komponentno cepivo] (ap) in/ali otroški ohromelosti [inaktivirano cepivo] (IPV) (cepiva dTap, dT-IPV, dTap-IPV), vendar na drugem vbodnem mestu (drugem delu telesa, npr. na drugi roki ali nogi).
Persistence of immune response to Gardasil 9 
Trajanje imunskega odziva na cepivo Gardasil 9
GDS07C/Protocol 020 evaluated immunogenicity of Gardasil 9 in men aged 16 to 26 years (N=500; 249 receiving Gardasil 9 and 251 receiving qHPV vaccine). 
GDS07C/Protokol 020 je ovrednotil imunogenost cepiva Gardasil 9 pri moških, starih 16 do 26 let (N = 500; 249 jih je prejelo cepivo Gardasil 9 in 251 qHPV cepivo).
Do not receive Gardasil 9 if you or your child 
Cepiva Gardasil 9 vi ali vaš otrok ne smete prejeti
Do not use this vaccine after the expiry date which is stated on the carton and syringe label after EXP. 
Tega cepiva ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli in nalepki injekcijske brizge poleg oznake EXP. Rok uporabnosti cepiva se izteče na zadnji dan navedenega meseca.
If a scheduled injection is missed, your doctor will decide when to give the missed dose. 
Če izpustite predvideni odmerek, bo čas cepljenja z izpuščenim odmerkom določil zdravnik.
• Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine 
• predrakavim lezijam in rakom materničnega vratu, vulve, nožnice in anusa, ki jih povzročajo tipi HPV, vsebovani v cepivu,
Seropositivity to vaccine HPV types in the per protocol population ranged from 98.3 to 100% by Month 7 in individuals who received Gardasil 9. 
Seropozitivnost za tipe HPV v cepivu je do 7. meseca v populaciji po protokolu pri osebah, ki so prejele cepivo Gardasil 9, segala od 98,3 do 100 %.
It is recommended that individuals who receive a first dose of Gardasil 9 complete the vaccination course with Gardasil 9. 
Priporočljivo je, da osebe, ki so prejele prvi odmerek cepiva Gardasil 9, cepljenje dokončajo s cepivom Gardasil 9.
GMTs were higher in girls and boys who received 2 doses of Gardasil 9 (at either 0, 6 months or 0, 12 months) than in girls and women 16 to 26 years of age who received 3 doses of Gardasil 9 (at 0, 2, 6 months) for each of the 9 vaccine HPV types. 
GMT so bili višji pri deklicah in dečkih, ki so prejeli 2 odmerka cepiva Gardasil 9 (v 0. in 6. mesecu ali 0. in 12. mesecu) kot pri deklicah in ženskah, starih 16 do 26 let, ki so prejele 3 odmerke cepiva Gardasil 9 (v 0., 2., 6. mesecu) za vsakega izmed 9 tipov HPV v cepivu.
Protocol 004 evaluated immunogenicity of Gardasil 9 in women aged 16 to 45 years (N=1,210: 640 women aged 27 to 45 years and 570 women aged 16 to 26 years). 
Protokol 004 je ovrednotil imunogenost cepiva Gardasil 9 pri ženskah, starih 16 do 45 let (N = 1.210: 640 žensk, starih 27 do 45 let, in 570 žensk, starih 16 do 26 let).
At Month 36, the GMTs in girls and boys aged 9 to 14 years receiving 2 doses at a 6-month interval (+/- 1-month) remained non-inferior to GMTs in women aged 16 to 26 years receiving 3 doses of Gardasil 9. 
V 36. mesecu so GMT pri deklicah in dečkih, starih 9 do 14 let, ki so prejeli 2 odmerka v razmiku 6 mesecev (+/- 1 mesec), ostali neinferiorni GMT pri ženskah, starih 16 do 26 let, ki so prejele 3 odmerke cepiva Gardasil 9.
• demonstration of non-inferior immunogenicity between Gardasil 9 and the qHPV vaccine for HPV types 6, 11, 16 and 18 in girls aged 9 to 15 years, women and men aged 16 to 26 years; efficacy for Gardasil 9 against persistent infection and disease related to HPV types 6, 11, 16, or 18 can be inferred to be comparable to that of the qHPV vaccine. 
• dokazani neinferiorni imunogenosti cepiva Gardasil 9 v primerjavi s qHPV cepivom za tipe HPV 6, 11, 16 in 18 pri deklicah, starih 9 do 15 let, ter ženskah in moških, starih 16 do 26 let; glede na to je mogoče sklepati, da je učinkovitost cepiva Gardasil 9 proti persistentni okužbi in bolezni, povezani s tipi HPV 6, 11, 16 in 18, podobna učinkovitosti qHPV cepiva,
On the basis of this immunogenicity bridging, the efficacy of a 2dose regimen of Gardasil 9 in girls and boys aged 9 to 14 years is inferred. 
Na osnovi primerjave imunogenosti lahko sklepamo o učinkovitosti 2-odmerne sheme cepljenja s cepivom Gardasil 9 pri deklicah in dečkih, starih 9 do 14 let.
Protocol 010 measured HPV antibody responses to the 9 HPV types after Gardasil 9 vaccination in the following cohorts: girls and boys aged 9 to 14 years receiving 2 doses at a 6-month or 12-month interval (+/- 1-month); girls aged 9 to 14 years receiving 3 doses (at 0, 2, 6 months); and women aged 16 to 26 years receiving 3 doses (at 0, 2, 6 months). 
Protokol 010 je ovrednotil odziv protiteles proti HPV na 9 tipov HPV po cepljenju s cepivom Gardasil 9 v naslednjih kohortah: deklice in dečki, stari 9 do 14 let, ki so prejeli 2 odmerka v razmiku 6 mesecev ali 12 mesecev (+/- 1 mesec); deklice, stare 9 do 14 let, ki so prejele 3 odmerke (v 0., 2. in 6. mesecu); in ženske, stare 16 do 26 let, ki so prejele 3 odmerke (v 0., 2., 6. mesecu).
Syncope (fainting), sometimes associated with falling, can occur following, or even before, any vaccination, especially in adolescents as a psychogenic response to the needle injection. 
Po katerem koli cepljenju ali celo pred njim se, še posebej pri mladostnikih, kot psihogeni odziv na injiciranje z iglo lahko pojavi sinkopa (omedlevica), včasih povezana s padcem.
Common (may affect up to 1 in 10 people): side effects found at the injection site (bruising, and itching), fever, tiredness, dizziness and nausea. 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): neželeni učinki na mestu injiciranja (modrice in srbenje), zvišana telesna temperatura, utrujenost, omotica in siljenje na bruhanje.
In Protocol 001registry study, no cases of vaccine HPV types related high-grade CIN were observed through 7.6 years postdose 3 (median follow-up of 4.4 years) in women (n = 1,782) who were aged 16 to 26 years at time of vaccination with Gardasil 9. 
V Protokolu 001, študiji na podlagi podatkov iz registra, niso opazili primerov CIN visoke stopnje, poveznih s tipi HPV v cepivu, tekom 7,6 let po 3. odmerku (mediani čas spremljanja 4,4 leta) pri ženskah (n = 1.782), ob cepljenju s cepivom Gardasil 9 starih 16 do 26 let.
Gardasil 9 is given as an injection by your doctor. 
Cepivo Gardasil 9 v obliki injekcije da zdravnik.
Pre-filled syringe with 2 needles, pack of 1, 10 
PODATKI NA ZUNANJI OVOJNINI BESEDILO NA ŠKATLI napolnjena injekcijska brizga z 2 iglama, pakiranje po 1, 10
Protocol 010 evaluated the immunogenicity of 2 doses of Gardasil 9 in girls and boys aged 9 to 14 years and 3 doses of Gardasil 9 in girls aged 9 to 14 years and women aged 16 to 26 years (N=1,518; 753 girls; 451 boys and 314 women). 
Protokol 010 je ovrednotil imunogenost 2 odmerkov cepiva Gardasil 9 pri deklicah in dečkih, starih 9 do 14 let, ter 3 odmerkov cepiva Gardasil 9 pri deklicah, starih 9 do 14 let, in ženskah, starih 16 do 26 let (N = 1.518; 753 deklic; 451 dečkov in 314 žensk).
Protocol 006 evaluated administration of Gardasil 9 to girls and women aged 12 to 26 years previously vaccinated with qHPV vaccine (N=921; 615 receiving Gardasil 9 and 306 receiving placebo). 
Protokol 006 je ovrednotil uporabo cepiva Gardasil 9 pri deklicah in ženskah, starih 12 do 26 let, predhodno cepljenih s qHPV cepivom (N = 921; 615 jih je prejelo cepivo Gardasil 9 in 306 placebo).
Single dose vial, pack of 1 
PODATKI NA ZUNANJI OVOJNINI BESEDILO NA ŠKATLI enoodmerna viala, pakiranje po 1
Gardasil 9 suspension for injection: 
Gardasil 9 suspenzija za injiciranje:
Gardasil 9 administered to female rats had no effects on mating performance, fertility, or embryonic/foetal development. 
Cepivo Gardasil 9, uporabljeno pri podganjih samicah, ni vplivalo na sposobnost parjenja, plodnost ali razvoj zarodka/ploda.
In 16- through 26- year-old women (N=20,541) efficacy against HPV 16- and 18-related CIN2/3, AIS or cervical cancer was 98.2% (95% CI: 93.5, 99.8) based on follow-up to 4 years (median 3.6 years); efficacy against HPV 6, 11, 16 or 18-related diseases was 96.0% (95% CI: 92.3, 98.2) for CIN or AIS, 100% (95% CI: 67.2, 100) for VIN2/3, 100% (95% CI: 55.4, 100) for VaIN2/3, and 99.0% (95% CI: 96.2, 99.9) for genital warts. 
Pri ženskah, starih 16 do 26 let (N = 20.541), je bila učinkovitost proti s HPV 16 in 18 povezanimi CIN2/3, AIS ali rakom materničnega vratu 98,2 % (95 % IZ: 93,5; 99,8) na podlagi do 4 letnega spremljanja (mediana 3,6 leta); učinkovitost proti s HPV 6, 11, 16 ali 18 povezanimi boleznimi je bila 96,0 % (95 % IZ: 92,3; 98,2) za CIN ali AIS, 100 % (95 % IZ: 67,2; 100) za VIN2/3, 100 % (95 % IZ: 55,4; 100) za VaIN2/3 in 99,0 % (95 % IZ: 96,2; 99,9) za genitalne bradavice.
Gardasil 9 is intended for adolescents and adults from 9 years of age onwards. 
Cepivo Gardasil 9 je namenjeno mladostnikom in odraslim, starim 9 let ali več.
In 16- through 26- year-old men (N=4,055) efficacy against HPV 6, 11, 16 or 18-related diseases was 74.9% (95% CI: 8.8, 95.4) for AIN 2/3 (median duration of follow-up of 2.15 years), 100.0% (95% CI: -52.1, 100) for penile/perineal/perianal intraepithelial neoplasia (PIN) 1/2/3, and 89.3% (95% CI: 65.3, 97.9) for genital warts (median duration of follow-up of 4 years). 
Pri moških, starih 16 do 26 let (N = 4.055), je bila učinkovitost proti s HPV 6, 11, 16 in 18 povezanimi boleznimi 74,9 % (95 % IZ: 8,8; 95,4) za AIN 2/3 (mediani čas spremljanja 2,15 leta), 100,0 % (95 % IZ: -52,1; 100) za penilno/perinealno/perianalno intraepitelijsko neoplazijo (PIN) 1/2/3 in 89,3 % (95 % IZ: 65,3; 97,9) za genitalne bradavice (mediani čas spremljanja 4 leta).
Protocol 003 evaluated immunogenicity of Gardasil 9 in men aged 16 to 26 years and women aged 16 to 26 years (N=2,515:1,103 Heterosexual Men [HM]; 313 Men Who Have Sex with Men [MSM]; and 1,099 women receiving Gardasil 9). 
Protokol 003 je ovrednotil imunogenost cepiva Gardasil 9 pri moških in ženskah, starih 16 do 26 let (N = 2.515: 1.103 heteroseksualnih moških [HM], 313 moških, ki imajo spolne odnose z moškimi [MSM], in 1.099 ženskah, ki so prejeli cepivo Gardasil 9).
The following adverse experiences have been spontaneously reported during post-approval use of qHPV vaccine and may also be seen in post-marketing experience with Gardasil 9. 
Pri uporabi qHPV cepiva po pridobitvi dovoljenja za promet so spontano poročali o naslednjih neželenih učinkih, ki se lahko med obdobjem trženja pojavijo tudi pri cepivu Gardasil 9.
Not known 
Neznana bruhanje
HPV Type 11 and 18 L1 protein 
L1 protein HPV tipa 11 in 18
Long-term follow-up studies are currently ongoing to determine the duration of protection. 
Trenutno potekajo študije dolgoročnega spremljanja, ki bodo pokazale trajanje zaščite (glejte poglavje 5.1).
HPV Type 16 L1 protein 
L1 protein HPV tipa 16
It is given to protect against diseases caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58. 
Uporablja se za zaščito pred boleznimi, ki jih povzročajo tipi 6, 11, 16, 18, 31, 33, 45, 52 in 58 humanih papilomavirusov (HPV).
Immunogenicity bridging from qHPV Vaccine to Gardasil 9 for HPV types 6, 11, 16, 18 
Primerjava imunogenosti qHPV cepiva in cepiva Gardasil 9 za HPV tipe 6, 11, 16, 18
Studies supporting the efficacy of Gardasil 9 against HPV types 6, 11, 16, 18 
Študije, ki podpirajo učinkovitost cepiva Gardasil 9 proti HPV tipom 6, 11, 16 in 18
Protocol 002 evaluated immunogenicity of Gardasil 9 in girls and boys aged 9 to 15 years and women aged 16 to 26 years (N=3,066: 1,932 girls; 666 boys; and 468 women receiving Gardasil 9). 
Protokol 002 je ovrednotil imunogenost cepiva Gardasil 9 pri deklicah in dečkih, starih 9 do 15 let, in pri ženskah, starih 16 do 26 let (N = 3.066: 1.932 deklic, 666 dečkov in 468 žensk, ki so prejeli cepivo Gardasil 9).
In Protocol 020/GDS07C, anti-HPV antibody GMTs at Month 7 among boys and men (HM) aged 16 to 26 years were comparable to anti-HPV antibody GMTs among boys and men (HM) aged 16 to 26 years administered with the qHPV vaccine for HPV 6, 11, 16 and 18. 
V Protokolu 020/ GDS07C so bili GMT protiteles proti HPV v 7. mesecu pri dečkih in moških (HM), starih 16 do 26 let, podobni kot GMT protiteles pri dečkih in moških (HM), starih 16 do 26 let, ki so prejeli qHPV cepivo za tipe HPV 6,11,16 in 18.
**Subjects were followed for up to 67 months postdose 3(median 43 months postdose 3). 
HR = veliko tveganje (high risk) *število oseb z vsaj enim kontrolnim obiskom po 7. mesecu **Osebe so spremljali do 67 mesecev po 3. odmerku (mediana 43 mesecev po 3. odmerku).
A subset of subjects is being followed up for 10 to 14 years after Gardasil 9 vaccination for safety, immunogenicity, and effectiveness against clinical diseases related to the HPV types in the vaccine. 
Podskupino oseb trenutno spremljajo glede varnosti, imunogenosti in učinkovitosti pred kliničnimi boleznimi, povezanimi s tipi HPV v cepivu.
In Protocol 003, anti-HPV antibody GMTs at Month 7 among boys and men (HM) aged 16 to 26 years were comparable to anti-HPV antibody GMTs among girls and women aged 16 to 26 years for vaccine HPV types. 
V Protokolu 003 so bili GMT protiteles proti HPV v 7. mesecu pri dečkih in moških (heteroseksualni moški - HM), starih 16 do 26 let, podobni kot GMT protiteles proti tipom HPV v cepivu pri deklicah in ženskah, starih 16 do 26 let.
In a clinical trial that included 640 individuals aged 27 to 45 years and 570 individuals aged 16 to 26 years who received Gardasil 9, the safety profile of Gardasil 9 was comparable between the two age groups. 
Varnostni profil cepiva Gardasil 9 iz kliničnega preskušanja, kjer je cepivo Gardasil 9 prejelo 640 oseb, starih 27 do 45 let, in 570 oseb, starih 16 do 26 let, je primerljiv med obema starostnima skupinama.
Gardasil 9 was efficacious in preventing HPV 31-, 33-, 45-, 52-, and 58-related persistent infection and disease (Table 4). 
Cepivo Gardasil 9 je bilo učinkovito pri preprečevanju persistentne okužbe in bolezni, povezanih s HPV 31, 33, 45, 52 in 58 (preglednica 4).
Gardasil 9 is an adjuvanted non-infectious recombinant 9-valent vaccine. 
Cepivo Gardasil 9 je nekužno rekombinantno 9-valentno cepivo z adjuvansom.
The PPE population consisted of individuals who received all 3 vaccinations within one year of enrolment, did not have major deviations from the study protocol, were naïve (PCR negative and seronegative) to the relevant HPV type(s) (types 31, 33, 45, 52, and 58) prior to dose 1, and who remained PCR negative to the relevant HPV type(s) through one month postdose 3 (Month 7). 
V populaciji PPE so bile osebe, ki so prejele vse 3 odmerke cepiva v enem letu po vključitvi, niso imele večjih odklonov od protokola študije, niso bile v stiku (PCR negativne in seronegativne) z zadevnim tipom (zadevnimi tipi) HPV (tipi 31, 33, 45, 52 in 58) pred 1. odmerkom in so ostale PCR negativne za zadevni tip (zadevne tipe) HPV tekom 1 meseca po 3. odmerku (7. mesec).
30 micrograms 
30 mikrogramov
The efficacy of Gardasil 9 against cervical definitive therapy (including loop electrosurgical excision procedure [LEEP] or conisation) related to vaccine HPV types compared to qHPV vaccine was 90.7% (95% CI 76.3, 97.0) with 4/6,016 versus 43/6,018 cases. 
Učinkovitost cepiva Gardasil 9 glede definitivnih posegov na materničnem vratu (vključno z elektrokirurško ekscizijo z zanko [LEEP] ali konizacijo), povezanih s tipi HPV v cepivu, je bila v primerjavi s qHPV cepivom 90,7 % (95 % IZ: 76,3; 97,0) s številom primerov 4/6.016 v primerjavi s 43/6.018.
Gardasil 9 suspension for injection in a pre-filled syringe: 
Gardasil 9 suspenzija za injiciranje v napolnjeni injekcijski brizgi:
*The PPI population consisted of individuals who received all three vaccinations within predefined day ranges, did not have major deviations from the study protocol, met predefined criteria for the interval between the Month 6 and Month 7 visit, seronegative to the relevant HPV type(s) (types 6, 11, 16, and 18) prior to dose 1, and among 16 to 26 year old women, were PCR negative to the relevant HPV type(s) prior to dose 1 through one month postdose 3 (Month 7). 
*V populaciji PPI so bile osebe, ki so prejele vse 3 odmerke cepiva znotraj vnaprej določenega časovnega intervala, niso imele večjih odklonov od protokola študije, so izpolnjevale vnaprej določene kriterije glede razmika med obiskoma v 6. in 7. mesecu, so bile seronegativne za zadevni tip (zadevne tipe) HPV (tipi 6, 11, 16 in 18) pred 1. odmerkom, ter so bile ženske, stare 16 do 26 let, PCR negativne za zadevni tip (zadevne tipe) HPV pred 1. odmerkom do 1 meseca po 3. odmerku (7. mesec).
The efficacy of Gardasil 9 against cervical biopsy related to vaccine HPV types compared to qHPV vaccine was 95.9% (95% CI 92.7, 97.9) with 11/6,016 versus 262/6,018 cases. 
Učinkovitost cepiva Gardasil 9 glede biopsij materničnega vratu, povezanih s tipi HPV v cepivu, je bila v primerjavi s qHPV cepivom 95,9 % (95 % IZ: 92,7; 97,9) s številom primerov 11/6.016 v primerjavi z 262/6.018.
• Withdraw the 0.5 ml dose of vaccine from the single-dose vial using a sterile needle and syringe. 
• S sterilno iglo in injekcijsko brizgo iz enoodmerne viale izvlecite 0,5 ml odmerek cepiva.
In clinical studies 98.2% to 100% who received Gardasil 9 became seropositive for antibodies against all 9 vaccine types by Month 7 across all groups tested. 
V kliničnih študijah je v vseh testiranih skupinah do 7. meseca od 98,2 % do 100 % oseb, ki so prejele cepivo Gardasil 9, postalo seropozitivnih za protitelesa proti vsem 9 tipom v cepivu.
Human Papillomavirus 9-valent Vaccine 
9-valentno cepivo proti humanim papilomavirusom
In clinical studies 99.2% to 100% who received Gardasil 9 became seropositive for antibodies against all 9 vaccine types by Month 7 across all groups tested. 
V kliničnih študijah je v vseh testiranih skupinah do 7. meseca od 99,2 % do 100 % oseb, ki so prejele cepivo Gardasil 9, postalo seropozitivnih za protitelesa proti vsem 9 tipom v cepivu.
Antibodies against all 9 HPV types were transferred to the offspring during gestation and lactation. 
Med brejostjo in dojenjem so se protitelesa proti vsem 9 tipom HPV prenesla na mladiče.
The PPE population consisted of individuals: - who received all 3 vaccinations within 1 year of enrolment, without major deviations from the study protocol, - who were seronegative to the relevant vaccine HPV type(s) prior to dose 1 and among women aged 16 to 26 years, PCR negative to the relevant vaccine HPV type(s) prior to dose 1 through one month postdose 3 (Month 7). 
Populacija PPE je vključevala posameznike, ki: - so prejeli vse 3 odmerke cepiva v 1 letu po vključitvi, niso imeli večjih odklonov od protokola študije, - so bili seronegativni za zadevni tip (zadevne tipe) HPV v cepivu pred 1. odmerkom in med ženskami starimi 16 do 26 let, PCR negativnimi za zadevni tip (zadevne tipe) HPV v cepivu pred 1. odmerkom in tekom enega meseca po 3. odmerku (7. mesec).
Persistent infection detected in samples from two or more consecutive visits 6 months (±1 month visit windows) apart. 
N = število oseb, randomiziranih v skupino s posameznim cepivom, ki so prejele vsaj eno injekcijo n = število oseb, vključenih v analizo persistentna okužba, odkrita v vzorcih z dveh ali več zaporednih obiskov v razmiku 6 mesecev (okno ± 1 mesec) persistentna okužba, odkrita v vzorcih s treh ali več zaporednih obiskov v razmiku 6 mesecev (okno ± 1 mesec) Papanicolaouov test
Gardasil 9 suspension for injection Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed) 
Gardasil 9 suspenzija za injiciranje 9-valentno cepivo proti humanim papilomavirusom (rekombinantno, adsorbirano)
• Inject immediately using the intramuscular (IM) route, preferably in the deltoid area of the upper arm or in the higher anterolateral area of the thigh. 
Najbolje je, da se ga aplicira v deltoidni predel nadlakti ali v zgornji anterolateralni predel stegna.
Individuals 9 to and including 14 years of age at time of first injection Gardasil 9 can be administered according to a 2-dose (0, 6 - 12 months) schedule (see section 5.1). 
Posamezniki od 9. do vključno 14. leta starosti ob prejemu prve injekcije Cepivo Gardasil 9 se lahko aplicira v skladu z 2-odmerno shemo cepljenja (0., 6.
• developed an allergic reaction after receiving a dose of Gardasil or Silgard (HPV types 6, 11, 16, and 18) or Gardasil 9. 
• če se je pri vas ali vašem otroku po cepljenju s predhodnim odmerkom cepiva Gardasil oz. Silgard (HPV tipi 6, 11, 16 in 18) ali cepiva Gardasil 9 pojavila alergijska reakcija.
Gardasil 9 suspension for injection in a pre-filled syringe Human Papillomavirus 9-valent Vaccine (Recombinant, adsorbed) 
Gardasil 9 suspenzija za injiciranje v napolnjeni injekcijski brizgi 9-valentno cepivo proti humanim papilomavirusom (rekombinantno, adsorbirano)
Anti-HPV responses at Month 7 among girls/boys aged 9 to 15 years were comparable to anti-HPV responses in women aged 16 to 26 years in the combined database of immunogenicity studies for Gardasil 9. 
V kombinirani podatkovni bazi študij imunogenosti cepiva Gardasil 9 so bili anti-HPV odzivi v 7. mesecu pri deklicah/dečkih, starih 9 do 15 let, podobni kot anti-HPV odzivi pri ženskah, starih 16 do 26 let.
Asthenia, chills, malaise 
Neznana astenija, mrzlica, splošno slabo počutje
Shake well before use. 
intramuskularna uporaba Pred uporabo dobro pretresite!
What other important information should you or your child know about Gardasil 9 
Drugi pomembni podatki o cepivu Gardasil 9, ki jih morate vi ali vaš otrok poznati
Gardasil 9 suspension for injection. 
Gardasil 9 suspenzija za injiciranje
When Gardasil 9 was given with a combined diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] booster vaccine during the same visit, there was more injection-site swelling. 
Pri sočasnem cepljenju (ob istem obisku) s cepivom Gardasil 9 in obnovitvenim odmerkom mešanega cepiva proti davici, tetanusu, oslovskemu kašlju [acelularno, komponentno cepivo] in otroški ohromelosti [inaktivirano cepivo] je bilo več primerov otekanja na mestu injiciranja.
The GMTs to HPV types 6, 11, 16, 18 were higher than in the population who had not previously received qHPV vaccine in other studies whereas the 
GMT za tipe HPV 6, 11, 16 in 18 so bili višji kot v populaciji, ki predhodno ni prejela qHPV cepiva v drugih študijah, GMT za tipe HPV 31, 33, 45, 52 in 58 pa so bili nižji.
• Choose an appropriate needle to ensure an intramuscular (IM) administration depending on your patient's size and weight. 
• Glede na bolnikovo velikost in telesno maso izberite ustrezno iglo za intramuskularno (i.m.)
Efficacy evaluation of Gardasil 9 against cervical high grade diseases caused by vaccine HPV types in the PPE 
Dodatno ovrednotenje učinkovitosti cepiva Gardasil 9 proti tipom HPV v cepivu
No clinical study of Gardasil 9 was conducted in HIV-infected individuals. 
Pri osebah, okuženih s HIV, niso izvedli nobene klinične študije s cepivom Gardasil 9.
What Gardasil 9 contains 
Kaj vsebuje cepivo Gardasil 9
The efficacy of Gardasil 9 against CIN 2 and worse related to vaccine HPV types compared to qHPV vaccine was 94.4% (95% CI 78.8, 99.0) with 2/5,952 versus 36/5,947 cases. 
Ovrednotenje učinkovitosti cepiva Gardasil 9 proti boleznim materničnega vratu visoke stopnje, ki jih povzročajo tipi HPV v cepivu, v populaciji PPE Učinkovitost cepiva Gardasil 9 proti CIN 2 in hujšim, povezanim s tipi HPV v cepivu, je bila v primerjavi s qHPV cepivom 94,4 % (95 % IZ: 78,8; 99,0) s številom primerov 2/5.952 v primerjavi s 36/5.947.